The primary purpose of this study is to determine whether the treatment with AZD9668 will
affect the metabolism and effect of Warfarin.
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Pharmacodynamics measured by maximum international normalised ratio ( INRmax)
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Male.
Inclusion Criteria:
- Provision of signed informed consent (including genotyping screening sample for
CYP2C9 and VKORC1) prior to any study specific procedures
- Subjects must be willing to use a barrier method of contraception, unless their
partners are post-menopausal or surgically sterile, or if a female partner is of
childbearing potential the subject must use a barrier method of contraception
(condom) and the partner must use accepted contraceptive methods (oral contraceptive,
implant, long term injectable contraceptive or intrauterine device), from first dose
of IP (warfarin and AZD9668) until 3 months after last dose of IP (warfarin and
AZD9668)
- Have a body mass index between 19 and 30 kg/m2 (inclusive) and a weight between 50
and 100 kg (inclusive)
- Be a non-smoker or ex-smoker who has stopped smoking for >6 months prior to Visit 1.
Exclusion Criteria:
- Any clinically significant disease or disorder
- Subject predicted to have high sensitivity to warfarin based on CYP2C9 and VKORC1
genotypes
- Any clinically relevant abnormal findings in physical examination